Old Problem, New Concerns: Hypercortisolemia in the Time of COVID-19
The ongoing coronavirus disease 2019 (COVID-19) pandemic forced a change in the way we provide medical treatment. Endocrinology in the era of COVID-19 had to transform and reduce its vast potential to the absolute necessities. Medical professionals needed to update their clinical practice to provide...
Saved in:
Published in | Frontiers in endocrinology (Lausanne) Vol. 12; p. 711612 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
05.10.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The ongoing coronavirus disease 2019 (COVID-19) pandemic forced a change in the way we provide medical treatment. Endocrinology in the era of COVID-19 had to transform and reduce its vast potential to the absolute necessities. Medical professionals needed to update their clinical practice to provide their patients as much support and as little harm as possible in these increasingly difficult times. International expert statements were published to offer guidance regarding proper care. It was suggested to simplify the diagnostic scheme of hypercortisolemia and to modify the approach to treatment. Hypercortisolemic patients with COVID-19 and iatrogenic hypercortisolemia due to glucocorticoid use are important clinical scenarios – we aimed to provide a cohesive summary of issues to consider. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 This article was submitted to Pituitary Endocrinology, a section of the journal Frontiers in Endocrinology These authors have contributed equally to this work Edited by: Jeff M. P. Holly, University of Bristol, United Kingdom Reviewed by: Gherardo Mazziotti, University of Milan, Italy; Dimitra Argyro Vassiliadi, University General Hospital Attikon, Greece |
ISSN: | 1664-2392 1664-2392 |
DOI: | 10.3389/fendo.2021.711612 |